A recently developed, adaptive constant-current electroporation technique was used to immunize mice with an intramuscular injection of plasmid coding for the extracellular and transmembrane domains of the product of the rat neu 664V-E oncogene protein.
Introduction
Viable DNA vaccine candidates for human cancer have to overcome the same major hurdle as other plasmid-based biologics: how to increase efficacy without vastly increasing the dose. Recent technological advancements in increasing DNA vaccine uptake and expression using a constant-current electroporation (CCE) technique, could help to overcome this limitation. [1] [2] [3] Many recent studies using in vivo electroporation to enhance the uptake and expression of DNA vaccines have been performed with high doses of plasmid and voltagebased methods. This technique involves delivering a predetermined voltage between the electrodes, without taking into account the resistance of the tissue to be treated. In a previous study, 4 we have measured the tissue resistance of muscles in different species, and determined that it can vary from subject to subject, from muscle to muscle within the same animal and during the electroporation due to cellular uptake of the formulation volume. The CELLECTRAt device is able to measure the tissue resistance before, between and during the electroporation pulses and adjust the voltage to account for these individual changes. This feature allows the device to maintain a true constant-current and a square wave through the muscle tissue during electroporation, preventing heating of a tissue 5 and consequently reducing tissue damage and pain, as well as contributing to the overall increase in plasmid uptake and expression. 4, 6 There have been numerous reviews of the advantages and disadvantages of various models of cancer vaccine, therapeutic versus prophylactic vaccines and transplantable versus autochthonous tumors 7 as well as the current tools such as adjuvants that have been used to enhance the immune responses generated by the vaccines. 8 Furthermore, there has been a recent surge in interest in using electroporation to enhance the delivery of plasmids or drugs with anti-tumor effects, as reviewed by Gothelf et al. 9 and Heller et al.
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Female BALB/c mice transgenic for the transforming rat neu 664VÀE oncogenes (BALB-neuT 664VÀE mice) display p185 neu , the protein product of rat neu oncogene, on the surface of the cells of their rudimentary mammary glands at 3 weeks of age. As a natural consequence of p185 neu overexpression and signal transduction, foci of atypical hyperplasia appear first in the terminal buds and then as lateral buds sprouting from ducts and ductules in all the 10 glands. The lateral buds give rise to foci of carcinoma in situ around the 15 th week, progressing to invasive lobular carcinomas by the 20th week. Carcinomas are present in all glands 10 weeks later and are palpable by the 33 rd week.
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Mammary carcinomas in BALB-neuT 664VÀE mice exhibit either a partial or complete downregulation of MHC class I expression, perhaps as a method to escape immune recognition. 12 Induction of an immune response able to protect against neu-driven carcinogenesis is thus a daunting challenge. 13 We have previously demonstrated prevention of tumor growth using a plasmid coding for the extracellular and transmembrane domains of the p185 neu (EC-TM plasmid). 14 In the present paper, we are presenting optimization studies to deliver cancer vaccines using the CCE method. We were able to induce long-term protection in BALB-neuT 664VÀE mice using a substantially reduced dose compared to classical voltage-based electroporation of plasmid vaccines using this technique, which may be important for further clinical developments of this technology, including possible clinical trials. A single vaccination using this regimen was able to prevent the formation of multifocal, pre-neoplastic lesions in all mammary glands, and vaccinations in 10 week intervals were able to keep all BALB-neuT 664VÀE mice free from tumors to more than one year of age.
Materials and methods

Mice
Female BALB/c mice (6-weeks old) were purchased at Charles River Laboratories (Calco, Italy). BALBneuT 664VÀE mice were bred under specific pathogen-free conditions by Charles River (Calco, Italy). BALBneuT 664VÀE mice knocked out for Fc-gRI/III (BALBneuT 664VÀE/ FcgRI/III) were generated by crossing BALB-neuT 664VÀE mice with BALB/c mice KO for the FcgRI/III receptor, kindly provided by Dr R Clynes (Columbia University, NY). Mammary glands were inspected at weekly intervals to note tumor appearance. Tumor masses were measured with calipers in two perpendicular diameters. Progressively growing masses of more that 1 mm mean diameter were regarded as tumors. Percentage of mice without tumor (tumor-free mice) was evaluated. Mice were treated according to the European Union guidelines.
Plasmid and electroporation
The pcDNA3 vector coding the extracellular and transmembrane domains of p185 neu (EC-TM plasmid) was produced and used as previously described. 15 Briefly, DNA was precipitated, suspended in sterile saline at 1 mg ml
À1
, and stored in aliquots at À20 1C for use in immunization protocols. For DNA electroporation, EC-TM or pcDNA3 plasmid in 25 ml sterile water with 0.1% poly-L-glutamate were injected into the gastrocnemius muscle of anesthetized mice. 4 Animals were injected with 5-50 mg of plasmid at each time specified. Two constant-current square-wave pulses of 20 ms in duration of 1 s between pulses were applied after 4 s using CELLECTRAt device and micro-electrodes (VGX Pharmaceuticals, Immune Therapeutics Division, The Woodlands, TX). Micro-electrodes are in an isosceles triangle shape with the long sides 5 mm and the short side 3 mm apart. A constant-current setting of 0.2 A was used for all cancer vaccine experiments, except for the electroporation conditions experiment in which 0.2, 0.3 and 0.4 A were used. The muscle resistance was measured to be between 800 and 1000 O, with the calculated voltage between 160 and 195 V.
Assessment of anti-p185
neu antibody Sera from BALB/c mice were collected 2, 4 or 6 weeks after vaccination and diluted 1:50 in PBS-azide-bovine serum albumin (PBS-azide-BSA) (Sigma-Aldrich, St Louis, MO). The presence of anti-p185 neu antibodies was determined by flow cytometry using BALB/c NIH3T3 fibroblasts, wild-type or stably co-transfected with the wild-type p185 neu mouse class I H-2K d and B7.1 genes (BALB/c NIH3T3-NKB). FITC-conjugated goat anti-mouse antibodies specific for mouse IgG Fc (DakoCytomation, Italy), were used to detect bound primary antibodies. Normal mouse serum was the negative control. The monoclonal Ab4 antibodies (Oncogene Research Products, Cambridge, MA, USA), which recognizes an extracellular domain of p185 neu protein, were used as a positive control. Serial Ab4 dilutions were used to generate a standard curve to determine the concentration (mg ml
À1
) of anti-p185 neu antibodies in serum. Flow cytometry analysis was performed with CyAn ADP (DakoCytomation, Italy). Isotype determination was carried out by an indirect immunofluorescence procedure. Dilution (1:20) of sera in PBS-azide-BSA were incubated with 2 Â 10 5 BALB/c NIH3T3-NKB cells for 45 min at 4 1C. After washing, the cells were incubated for 30 min with rat biotin-conjugated antibodies antimouse IgG1, IgG2a, IgG2b and IgG3 (Caltag Laboratories, Burlingame, CA), and then for 30 min with 5 ml of streptavidin-phycoertrin (DAKO) and resuspended in PBS-azide-BSA containing 1 mg ml À1 propidium iodide. Samples were evaluated by CyAn ADP and data are reported as the percentage of p185 neu þ cells.
In vivo cytotoxicity assay
In vivo cytotoxicity assay was performed as described by Ritchie et al., 16 with slight modifications. Briefly, a singlecell suspension of 10 7 naive Spc ml À1 was labeled with two different concentrations (0.5 or 5.0 mM) of the fluorescent dye CFSE (Molecular Probes, Leiden, The Netherlands). Spc labeled with 5 mM were also pulsed with p185 neu (63-71) 9-mer peptide with H-2K d restriction element 17 for 1 h at room temperature. The two Spc populations were mixed together in equal amounts and injected intravenously into control and electroporated mice. BALB/c mice were killed 14, 28 and 42 days after vaccination, and single-cell suspensions from spleens were processed individually to evaluate the presence of highand low-CFSE cells by CyAn ADP. The specific cytolytic activity was calculated as: 100 Â (percentage CFSE-low cellsÀpercentage CFSE-high cells)/percentage CFSE-low cells.
18
Cell line and tumor challenge TUBO cells 15 are a cloned line derived from a mammary carcinoma of a BALB-neuT 664VÀE female. p185 neu is highly expressed on the cell membrane of TUBO cells that were cultured in DMEM with 20% FBS. Mice were challenged subcutaneously in the left flank with 0.2 ml of a single suspension containing the minimal lethal dose of TUBO cells (10 5 ). The cages were coded, and the incidence and the growth of tumors were evaluated twice weekly with the investigator blinded to the treatment group. Neoplastic masses were measured with calipers in the two perpendicular diameters. At the end of this period, tumor-free mice were classed as survivors. Mice were killed for humane reasons when the tumor exceeded 10 mm in mean diameter. Data from two independently performed experiments were cumulated, as they yielded identical results.
Results
Induction of anti-p185
neu response in wild-type BALB/c mice Mice were injected with 50 mg of EC-TM plasmid and administered CCE at different constant current-settings from 0.2-0.4 A (Figure 1) . Since, the most evident immune response induced by vaccination with EC-TM plasmids is the rise of anti-p185 neu antibodies, 15 two weeks after vaccination sera were collected and the specific antibody titers were evaluated. The titer of antip185
neu antibodies elicited appears to be inversely proportional to the intensity of the electric current amperage, although the differences were not statistically significant. The lowest current setting, 0.2 A, was then used for all the other experiments. Induction of antibodies to p185 neu protein was then evaluated in mice constant current electroporated with increasing doses of EC-TM plasmid. Sera from individual mice collected 2 and 4 weeks after CCE showed that all doses of EC-TM plasmid were able to induce anti-p185 neu antibodies at both 2 (data not shown) and 4 weeks after vaccination. Four weeks after electroporation, sera from mice constant current electroporated with 50 mg of EC-TM plasmid showed the highest titers (Figure 2a ). In addition, sera collected 2 weeks after CCE were pooled to evaluate isotype composition of anti-p185 neu antibodies, showing that the 0.2 A condition strongly induces an isotype Figure 1 The optimal current voltage for EC-TM plasmid electroporation assessed in function of the serum antibody. BALB/c mice were vaccinated with 50 mg of EC-TM plasmid and electroporated with 0.2, 0.3 or 0.4 A. Two weeks later sera were collected and the specific antibody titers were evaluated. While no statistically significant differences were evident, a trend toward an inverse correlation between the current intensity (Amperes, A) of CCE and the antibody response was detected. Each symbol indicates the average sera of an individual mouse, while the horizontal bars indicate the median value. DNA electroporation prevents mammary carcinomas C Curcio et al switch to IgG2a (Figure 2b ), the most effective one for antitumor activity against neu þ tumors. 15 It was previously shown 19 that effective EC-TM vaccination of BALB/c mice is able to induce a cytotoxic response against the immunodominant p185 neu (63-71) 9-mer peptide. 15 To assess whether the 0.2 A CCE condition used with EC-TM plasmids was also able to induce a cytotoxic T-cell response, BALB/c mice constant current electroporated with 50 mg of empty vector or vector coding for EC-TM plasmid were analyzed in vivo for their cytotoxic activity against syngeneic spleen cells pulsed with the immunodominant (63-71) 9-mer peptide ( Figure 3) . A cytotoxic response was evident 14 days after CCE of EC-TM plasmid and was still evident 28 and 42 days later.
Rejection of a neu
þ tumor cell challenge by wild-type BALB/c mice A dose-response experiment was set up to examine the effects of escalating doses of EC-TM plasmid constant current electroporated on the ability of BALB/c mice to reject a challenge of neu 664VÀE þ TUBO cells (Table 1) . Mice were vaccinated with 5, 10, 25 and 50 mg of EC-TM plasmid and CCE with 0.2 A. Forty-two days later, control and immunized mice were challenged with a lethal dose of TUBO cells (1 Â 10 5 ). All mice that received CEE of empty vector developed a fast-growing tumor by day 30, whereas all those vaccinated with 10, 25 or 50 mg of EC-TM plasmid remained tumor free for 150 days after challenge (192 days after vaccination). Interestingly, two out of eight of those constant current electroporated with 5 mg of EC-TM plasmid remained tumor free. When tumor-free mice were challenged again with TUBO cells, 206 days after the initial CCE (164 days after the first challenge), all remained tumor free 100 days after the second challenge, when the experiment was ended.
Inhibition of autochthonous carcinomas in transgenic BALB-neuT 664VÀE mice To assess the potential of EC-TM plasmid vaccination with CCE in the control of progressive stages of neudriven mammary carcinogenesis, transgenic BALBneuT 664VÀE mice were constant current electroporated with EC-TM plasmid every 10 weeks starting when they already display diffuse mammary atypical hyperplasia and multifocal in situ carcinomas in all their mammary glands (10 weeks of age). 20 All BALB-neuT 664VÀE and BALB-neuT 664VÀE /FcgRI/III KO mice injected with the empty vector pcDNA3 develop a tumor by day 160 (Figure 4a ). Eight out of nine BALB-neuT 664VÀE mice (89%) immunized with EC-TM were tumor free at 450 days of age. The appearance of tumors by day 170 in all BALB-neuT 664VÀE /FcgRI/III KO mice constant current electroporated with EC-TM (4/4) (Po0.0001 versus immunized BALB-neuT 664VÀE mice) suggests that ADCC play a major role in the protection elicited by CCE of EC-TM. Data from immunized BALB-neuT 664VÀE are from two independent experiments of four and five mice each that were cumulated as they provided homogeneous results.
Lastly, to further assess the potential of EC-TM plasmid vaccination using CCE, BALB-neuT 664VÀE mice in which the neu-driven carcinogenesis progressed for further 30 days to multiple microscopic invasive carcinomas, 20 were treated with EC-TM plasmid and CCE only once. Also in these stringent conditions, CCE of EC-TM plasmid afforded a significant delay of tumor appearance (Po0.0001 versus untreated mice and mice CCE with control pc-DNA3 plasmid) (Figure 4b ).
Discussion
Administration of a clinically relevant and efficacious dose is a major goal of every investigator using DNA vaccines in animal models. Electroporation has been shown to be an efficient method for enhancing the uptake and expression of DNA vaccine candidates, enabling the use of a lower dose of vaccine with similar or higher efficacy. 21 Previous studies have yielded exciting shortterm results but long-term prevention of tumor development with a minimum of intervention has remained elusive. To address these questions, we have designed and conducted the studies described herein. We have demonstrated in two independently conducted experiments that significantly lower doses of EC-TM plasmid in intramuscular injection followed by low-current intensity CCE, can be used to achieve long-term protection from breast carcinoma in both tumor implantation and transgenic mice models. This combination of low plasmid doses and mild electroporation conditions is paramount for the human development of the technology, where adverse effects from plasmid delivery (such as integration due to tissue damage 22 and pain or discomfort due to electroporation using high field intensity pulses 23 ) can be a significant problem.
Electroporation of cancer vaccines or drugs has been highlighted in recent reviews as an effective technique to either prevent tumor growth using intramuscular injections 14 or when combined with injections of interleukin-12 24 or eliminate existing tumors using intra-tumoral injections. 25, 26 While the latter technology has yielded very promising results in tumors located on the skin surface, an intramuscular vaccination procedure that is able to induce long-term immunity to the tumors, which may develop within the tissue is a more effective technique.
In the present study, two separate models of tumor development were studied: tumor implantation using TUBO cells and autochthonous tumor formation in BALB-neuT 664VÀE mice. There are advantages and disadvantages to each method. TUBO cell implantation is an effective method to quickly and accurately measure immunity to the vaccine candidate, however, it does not take into account the effects of the vaccine on spontaneous tumor formation. BALB-neuT 664VÀE mice are a more clinically relevant model for tumor formation, but experiments may last for a year or more to delineate significant effects on tumor development. Mice that develop a tumor as a consequence of a gene alteration inserted in their genome constitute a relatively new experimental model. In these mice, tumors progress slowly and by stages, and the relationship of neoplastic lesions with the surrounding tissues is preserved mirroring a few additional features of human cancer. 7 Constant current electroporation conditions were identified through previous experiments with reporter plasmids in mice. 4 However, the current setting (0.1 A) required to elicit optimum expression of secreted embryonic alkaline phosphatase in mice is lower than the current setting (0.2 A) in cancer vaccine experiments, which induces effective levels of IgG2 antibodies in the present study. Higher current settings (0.3 and 0.4 A) yielded less efficient electroporations, possibly with more muscle damage, leading to a decrease in EC-TM plasmid expression and thus, specific antibody titers. This difference may be explained by a higher degree of transient inflammation that is usually correlated with higher current settings that may be beneficial for delivery of a plasmid encoding for some vaccines versus therapeutic proteins. 27 The window of optimum settings is not wide in the case of vaccination. A setting that is too high may induce cellular damage and consequently lower vaccine expression, while a setting that is too low would not result in sufficient uptake and would actually lower vaccine expression.
In wild-type BALB/c mice, rat p185 neu is a xenogeneic protein that differs from mouse p185 neu at multiple epitopes. 28 In these mice, as little as 5 mg of EC-TM plasmid electroporated once using CCE affords a significant protection against a subsequent lethal challenge of neu þ carcinoma cells. Moreover, all BALB/c mice constant current electroporated with 10 mg were completely protected and developed a persistent immune memory. It is important to note that despite the relatively few animals per group in this portion of the study, the differences between the group treated with 10 mg (and above) were statistically different from controls.
Rat neu transgenic BALB-neuT 664VÀE female mice are genetically predestined to develop one of the most aggressive forms of multifocal mammary carcinogenesis with penetrance of all their mammary glands. 20 In these mice, cancer progression is straightforwardly driven by the transgenic neu oncogene that both provides abnormal growth signals and inhibits cell-death pathways. 29 Due to rat neu transgene expression in the thymus and overexpression in the mammary gland, the T-cell repertoire of these mice is markedly affected and CD8 þ T-cell clones reacting with dominant neu epitopes are deleted. 19 Moreover, during the progression of the mammary lesions both suppressor CD4
T-reg cells 18 and CD11b þ Gr1 þ immature myeloid cells, 30 expand. Despite the presence of these multiple negative immunological controls, a complete protection is afforded by EC-TM plasmid CCE started when mice display diffuse atypical hyperplasia and multifocal in situ carcinomas in all mammary glands and repeated every 70 days. Even more significant is the finding that a single EC-TM plasmid CCE done on 100-day-old BALB-neuT 664VÀE mice that already display multiple microscopic invasive carcinomas in all mammary glands markedly delays the progression of cancer lesion and keep about 50% of mice tumor free at one year of age.
Numerous studies performed immunizing BALBneuT 664VÀE mice with the EC-TM plasmids showed that the protection against neu-driven carcinogenesis in these mice mostly depends on the titer and isotype of antip185 neu antibodies elicited by the vaccine. 31, 32 Present data showing that the protection afforded by EC-TM CCE is null in BALB-neuT 664VÀE /FcgRI/III KO that are unable to mediate ADCC further endorse the indirect role of anti-p185 neu antibodies in this experimental system. Despite the numerous studies performed with the same EC-TM plasmid administered to BALB-neuT 664VÀE mice with different delivery systems, 31 a direct comparison of the efficacy may not be perfect since, subtle technical variations and small deviations in the timing of vaccine administration may lead to major differences in efficacy. Nevertheless, EC-TM CCE appears to be the most efficacious and practical way of eliciting very significant protection.
The enhancement in the efficacy and subsequently lowering of the effective DNA vaccine dose is beneficial from both a manufacturing (cost-effective) as well as a toxicological perspective. While plasmids manufactured under GMP have limited levels of endotoxins, residual genomic DNA or bacterial RNA, as plasmid-dose increases, the absolute levels of these contaminants increase and can negatively impact expression as well as increase the risk of adverse effects, both locally and systemically. 33 Distant site distribution and integration of plasmids at the injection site is thought to be correlated to the plasmid-dose and electroporation conditions, with higher current and voltage settings associated to higher risk of unwanted effect. 22 The ability to lower the dose and frequency of necessary vaccinations may allow this method to be both economically viable and safer by using less vaccine per human patient. The use of neu plasmids and CCE for long-term protection from breast carcinomas using lower doses and fewer vaccinations is an important breakthrough for the potential clinical relevance of this cancer vaccine regimen.
